ITEMS IN AFP WITH KEYWORD:
Attention Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder in childhood can persist into adulthood in at least 30 percent of patients, with 3 to 4 percent of adults meeting the Diagnostic and Statistical Manual of Mental Disorders, 4th ed., diagnostic criteria. A number of conditions, such as thyroid disease, mood di...
Mar 15, 2011 Issue
ICSI Releases Guideline on Diagnosis and Management of ADHD in Children [Practice Guidelines]
Attention-deficit/hyperactivity disorder (ADHD) is a common condition marked by inattention, hyperactivity, and impulsivity. The Institute for Clinical Systems Improvement (ICSI) has released guideline on diagnosis and management of ADHD in children.
Guanfacine is an effective short-term treatment option for ADHD in children six to 12 years of age. Sedation is a marked problem in many children. Patients should take the medication daily to avoid adverse effects that occur with abrupt discontinuation or when the guanfacine is restarted.
A recent guideline from the American Heart Association (AHA) recommended routine electrocardiography (ECG) in children before they begin pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD). That recommendation contradicts evidence-based recommendations from the American Academy of Ch...
Symptoms of childhood attention-deficit/hyperactivity disorder affect cognitive, academic, behavioral, emotional, social, and developmental functioning. Attention-deficit/hyperactivity disorder is the most commonly diagnosed neurodevelopmental disorder in children and adolescents. An estimated 2 to ...
Feb 15, 2006 Issue
CDC Releases Data on ADHD Diagnosis and Treatment in Children [Practice Guidelines]
A report analyzing the rate of diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD) among children and adolescents has been released by the Centers for Disease Control and Prevention (CDC).
Atomoxetine is more effective than placebo for treating symptoms of ADHD in children and adults, based on short-term studies. Given safety concerns (growth retardation, potential adverse effects in slow metabolizers) and its high cost, atomoxetine should be considered only as an alternative for pati...
The American Academy of Pediatrics (AAP) has issued a new guideline for the treatment of school-aged children (six to 12 years) with attention-deficit/hyperactivity disorder (ADHD).